Emergent Biodefense Operations Lansing LLC

Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense, manufactures BioThrax (anthrax vaccine adsorbed) and related biological products for the U.S. federal government as a prime contractor on a single-award indefinite delivery contract and related delivery orders, competing in full-and-open procurements with no set-aside designations. The company is a self-certified small disadvantaged business and for-profit manufacturer headquartered in Lansing, Michigan.

Emergent Biodefense's federal footprint is dominated by vaccine and biological-product manufacturing under NAICS 325414 (Biological Product Manufacturing) and PSC 6505 (Drugs and Biologicals). The vendor holds a $235.8 million single-award indefinite delivery contract (W911SR24D0001) issued by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense on January 9, 2024, with a period of performance through September 30, 2033, for procurement of BioThrax — the only FDA-licensed vaccine for anthrax prevention and a critical component of the U.S. government's strategic national stockpile. Recent delivery orders under this IDV include a $66.9 million order awarded January 4, 2026 (completion September 30, 2029) and a $41.8 million order awarded January 22, 2024 (completed September 30, 2025). The vendor also performs annual potency testing of WETVAX (APSV) vials under contract to the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response.

Customer concentration tilts heavily toward HHS components. The top five customer agencies account for 84% of award count and 99% of combined potential value. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response anchors the potential-value ranking with five awards worth $1.84 billion combined; HHS Centers for Disease Control and Prevention Pittsburgh follows with seven awards worth $1.51 billion. The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense accounts for four awards worth $344.5 million. The vendor operates across four named indefinite delivery contracts, with the Army's W911SR24D0001 carrying the highest combined potential value at $108.7 million across two task orders. Combined potential value across all 37 awards since 1997 stands at $5.74 billion, with $3.9 billion obligated. Recent activity remains sparse — two awards in 2024 and two in 2026 — reflecting the long-duration nature of strategic stockpile procurement.